AFFORDABLE MEDICINES SPEAKERS

Ismail Bel Bachir was appointed CEO of Tabuk Pharmaceuticals in 2010. He was instrumental in transforming the organization from a Saudi-based family business into a leading established pharmaceutical corporation focused on the MENA region. Recognized as a strategic leader, Ismail brought with him a ...

Dr. Cappuccino is currently the Vice-President and Head of Quality and Scientific Affairs for Dr. Reddy’s Laboratories Inc., located in Princeton, NJ, USA.Dr. Cappuccino also served as the Chief Executive Officer of Pharmaceutical Intellectual Resource Services LLC, in Lambertville, NJ USA. Prior...

Industry experience of close to 3 decades having handled sales, training, brand management, marketing and commercial operations. Current role includes commercial operations for vaccines & biologics and small molecules across specialties & geographies, Business Development, In & Out...

Raul has a degree in Business Science, MBA from ESADE and Master in Foreign Trade from the Community of European Management Schools (CEMS) in St Gallen, Switzerland. He has dedicated his entire career to the family business, within the chemical-pharmaceutical industries at The Indukern Group, in...

Pavel Farkas graduated and earned a Doctor of Pharmacy degree from J.A.Comenius University and Institute of Experimental Endocrinology of Slovak Academy of Sciences in Bratislava, Slovakia, completed a specialization degree in Clinical Pharmacy as the National Institute of Oncology in...

MOURAD FAROUK REZK, MD MSc MBASenior Director, Global Head of Medical and Scientific Affairs, Biosimilars Dr Mourad Rezk joined Biogen in January 2015. He is a medical doctor who trained as adiabetologist. He brings more than 20 years of experience in the pharmaceuticalindustry, holding a number of ...

Erika Geimonen serves as Vice President, Business Development for Amring Pharmaceuticals. She is responsible for analyzing the market landscape to identify opportunities in product licensing, partnering and acquisitions that will help Amring Pharmaceuticals reach its strategic objectives. She...

Jane Hippenmeyer was appointed Director of Scientific Affairs Amgen Biosimilars Europe in March 2016.  In this role she is responsible for the creation of Scientific Affairs structures in European affiliate countries, to prepare for the launch of Amgen Biosimilars in Oncology and Inflammation. Jane ...

David M. Jauch is responsible for Government Relations within Global Regulatory Affairs of Fresenius Kabi. He is the Chairman of the Global Policy and Market Committee, Member of the Board of Medicines for Europe as well as a member of the Trade Committees of IGBA (International Generics and...

Adam joined the biosimilars team in June 2015. He brings 13 years of market access experience, primarily from his time with Novo Nordisk in global, regional and affiliate roles including head of global market access and market access Europe. Prior to Novo Nordisk, Adam was responsible for Ilaris...

Dr. Liedert, trained as a pharmacologist, is familiar with both sides of the table, the developers´ objectives and the regulators´ perspective on biosimilars development: Today he is Senior Director, Clinical Development Biosimilars at Boehringer Ingelheim, guiding biosimilar monoclonal antibodies...

Patrick Liu, M.D., Ph.D., is Vice President of Global Biologics R&D and Head of Biologics, Assays and Technology at Teva Pharmaceuticals. Dr. Liu leads a global team with responsibilities from late stage research, through IND, clinical trials and marketing registration, with focus on product...

Luis has a broad experience in Customer and Patience Marketing and Commercial roles. He spent almost 10 years in Procter & Gamble, with positions in Spain and the UK. He was part of the business growth of key product categories and new products in both markets. He moved to Danone Infant milks...

PhD in Biomedicine.Academic research in gene therapy, regeneration and muscular dystrophy, diabetes.He has published numerous original research papers and review articles in peer reviewed journals.Expert in medical and scientific writing for...

Klaus Martin is a Senior Director at Polpharma Biologics and Chief Scientific Officer, leading global late-stage development, strategic marketing and medical affairs functions.  Klaus has been working on Biosimilars since 2002. He held global management positions at Sandoz Biopharmaceuticals, first ...

  Professor Bobby Prasad joined The Abraaj Group as Global Chief Medical Officer and is based in the London office.Professor Prasad is a Consultant Gastroenterologist and Visiting Professor at the University of West London and has been in clinical practice for over twenty years having worked at...

Joaquín Rodrigo es Licenciado en Administración y Dirección de Empresas por la Asturias Business School y por la San Francisco State University, Master en Marketing de la Industria Farmacéutica por el CESIF (Centro de Estudios Superiores de la Industria Farmacéutica), y MBA por el IE (Instituto de...

Karsten Roth, Director Clinical Operations at Cinfa Biotech, leads all of Cinfa Biotech’s clinical development programs. He is responsible for the development and implementation of preclinical, clinical and post-approval activities. He has more than 20 years of experience in the pharmaceutical...

Anjan Selz is Vice President – Head of Biosimilars EMEA, at Lupin Europe.In his current role, Anjan is structuring the market facing organization for Biosimilars at Lupin Europe and implementing the processes necessary to access the market with this new product portfolio.He has substantial...

Jennifer C. Smith-Parker is Deputy Editor of BioPharm Insight, and is responsible for managing a robust team of reporters and analysts in the London office. She joined BPI in October 2009, covering healthcare policy and regulatory news in Washington, DC. After developing excellent sources and...

Over 20 years in pharma industry with last 8 years working in the area of biosimilars. Formally Global Head of Medical Affairs at Sandoz biosimilars working on this exciting and rapidly evolving area of biosimilars. During this time I have experience in strategic planning and execution for medical...

Gopalakrishnan Venkatesan is the Vice President of Business Development at Wockhardt USA, the US subsidiary of Wockhardt Limited. Gopal has a graduate degree in Pharmaceutical Sciences and a MBA from the University of Bombay, India and has worked at Wockhardt since June 1987. Gopal has also...